A5046114292- Transplantation: Methods and Outcomes
- Mechanical Circulatory Support Devices
- Organ Transplantation Techniques and Outcomes
- Pulmonary Hypertension Research and Treatments
- Renal Transplantation Outcomes and Treatments
- Cardiac Arrest and Resuscitation
- Liver Disease and Transplantation
- Organ Donation and Transplantation
- Cardiac Valve Diseases and Treatments
- Cardiac Structural Anomalies and Repair
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cardiovascular Function and Risk Factors
- Respiratory Support and Mechanisms
- Cardiac Ischemia and Reperfusion
- Inhalation and Respiratory Drug Delivery
- Central Venous Catheters and Hemodialysis
- Xenotransplantation and immune response
- Lung Cancer Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Radiomics and Machine Learning in Medical Imaging
- Liver Disease Diagnosis and Treatment
- Polymer Surface Interaction Studies
- Cystic Fibrosis Research Advances
- Ultrasound and Hyperthermia Applications
- Neonatal Respiratory Health Research
Vanderbilt University Medical Center
2021-2025
VA Tennessee Valley Healthcare System
2024
Michigan Medicine
2021
Carnegie Mellon University
2019-2020
University of Michigan–Ann Arbor
2020
Columbia University Irving Medical Center
2013-2020
Texas Health Dallas
2020
Saint Vincent's Catholic Medical Center
2011
Inhibiting thrombosis without generating bleeding risks is a major challenge in medicine. A promising solution may be the inhibition of coagulation factor XII (FXII), because its knock-out or animals reduced causing abnormal bleeding. Herein, we have engineered macrocyclic peptide inhibitor activated FXII (FXIIa) with sub-nanomolar activity (Ki = 370 ± 40 pM) and high stability (t1/2 > 5 days plasma), allowing for preclinical evaluation first synthetic FXIIa inhibitor. This 1899 Da molecule,...
ABSTRACT Introduction Use of normothermic regional perfusion (NRP) to recover donation after circulatory death (DCD) organs demonstrates increased heart utilization with favorable outcomes. Conversely, DCD lung allograft use when NRP was employed remains controversial. This is a contemporary analysis recipient outcomes in which used. Methods Utilizing the STAR‐OPTN database, all adult recipients United States between January 1, 2020, and June 30, 2024 were identified. defined if time donor...
Access to life-saving lung transplantation remains limited by a shortage of donor organs. We have previously described rehabilitation discarded human lungs quality suitable for using cross-circulation whole blood between xeno-support swine and lungs. However, the immunologic implications transplanting rehabilitated remain unknown. Human declined clinical (N=5) underwent xenogeneic up 12 hours. To model subsequent transplantation, were re-exposed autologous via normothermic ex vivo machine...
Donor-derived cell-free DNA (dd-cfDNA%) is a biomarker of early acute lung allograft dysfunction (ALAD), with value ≥1.0% indicating injury. Whether dd-cfDNA% useful in patients >2 y posttransplant unknown. Our group previously demonstrated that median recipients ≥2 without ALAD was 0.45%. In cohort, biologic variability estimated by reference change (RCV) 73%, suggesting exceeding 73% may be pathologic. this study, we aimed to determine whether or absolute thresholds are optimal for detecting ALAD.
Improved approaches to expanding the pool of donor lungs suitable for transplantation are critically needed growing population with end-stage lung disease. Cross-circulation (XC) whole blood between swine and explanted human has previously been reported enable extracorporeal recovery that declined due acute, reversible injuries. However, immunologic interactions this xenogeneic platform have not characterized, thus limiting potential translational applications. Using flow cytometry...
Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in lung transplant recipients remain limited.We performed a single-center, observational study of diagnosed with SARS-CoV-2 between 5/1/2020 and 3/15/2022 that were followed for median 123 days. We analyzed changes spirometry, allograft dysfunction (ALAD) incidence, hospitalization, mechanical ventilation needs, secondary infection, survival.In our cohort 336 patients, 103 developed disease...
Background. Donor-derived cell-free DNA (dd-cfDNA) is a useful biomarker for the diagnosis of acute allograft injury within first 1 to 2 y after lung transplant, but its utility diagnosing chronic dysfunction (CLAD) has not yet been studied. Understanding baseline dd-cfDNA kinetics beyond initial posttransplant necessary step in determining as CLAD biomarker. We seek establish dd-cfDNA% levels clinically stable recipients who are >2 posttransplant. Methods. performed prospective,...
Decompensated right ventricular failure (RVF) in pulmonary hypertension (PH) is fatal, with limited medical treatment options. Developing and testing novel therapeutics for PH requires a clinically relevant large animal model of increased vascular resistance RVF. This manuscript discusses the latest development previously published ovine PH-RVF that utilizes left artery (PA) ligation main PA occlusion. versatile platform to control not only disease severity but also RV's phenotypic response....
Abstract Background Long-term use of extracorporeal membrane oxygenation (ECMO) remains limited because poor biocompatibility, which often leads to clot formation and device failure. Despite this common pathway failure, there are no published studies on the rate resulting performance deficits in current oxygenators. Methods ECMO cases with either Maquet’s CardioHelp (CH, n=28) or Quadrox (Qx, n=14) oxygenators were evaluated over a three-month period. Data was collected prospectively...